|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Also, mRNA expression of transcriptional marker Nanog and Octamer-binding transcription factor 4 (OCT4), known to enhance malignancy and metastasis in lung adenocarcinoma, was suppressed in ZNF746 siRNA-transfected H460 NSCLC cells.
|
24145959 |
2014 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
GeneticVariation |
BEFREE |
Egr1 exerts a promoting effect on cancer metastasis in Oct4-overexpressing lung cancer.
|
31399076 |
2019 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
These findings suggest that positive/high Oct-4 is more strongly linked to stage III/IV cancer and cancer grade of differentiation, and is correlated with malignant characteristics that lead to poor prognosis in different types of cancer, especially in Asian.
|
26575328 |
2016 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Further, various studies identified genes in cancer stem cells, which were previously shown to regulate the pluripotency circuitry, particularly the so-called "Yamanaka-Factors" (OCT4, KLF4, SOX2, and c-MYC).
|
26896855 |
2016 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The results demonstrated Wnt/β-catenin signaling was activated and was able to form mammospheres with increased cancer stem cell markers (ALDH1, NANOG, and OCT4) in endocrine-resistant cells.
|
31693936 |
2019 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
More importantly, the expression levels of epithelial-mesenchymal transition biomarkers (N-cadherin and vimentin) and cell stemness biomarkers (nanog, sox2, and oct3/4) considerably increased in HepG2 with dopamine-induced SULT1A3/4, whereas in L02, epithelial-mesenchymal transition and cancer stem cell-associated proteins were contrarily decreased.
|
29025375 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Furthermore, during ethanol-induced cellular transformation, cells gained the phenotypes of cancer stem cells (CSCs) by expressing pluripotency maintaining factors (Oct4, Sox2, cMyc and KLF4) and stem cell markers (CD24, CD44 and CD133).
|
29761897 |
2018 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Stemness state in cancer stem cells (CSCs) was evaluated by the changes of CSC biomarkers including Oct-4 and ABCG2.
|
26289851 |
2016 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Finally, we analyzed the expression and clinical significance of epithelial-to-mesenchymal transition (EMT) markers (E-cadherin and N-cadherin) and cancer stem cell (CSC) markers (Nanog, Oct-4, and Sox-2) in CRC tissues.
|
29081665 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
POU5F1 (OCT4) is implicated in cancer stem cell self-renewal.
|
31012189 |
2019 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The generation of induced pluripotent stem cells (iPSCs) from somatic cells by expressing ectopic reprogramming transcriptional factors such as Oct3/4, Sox2, Klf4, c-Myc, and Nanog is one of the cutting-edge discoveries in stem cell and cancer research.
|
24568610 |
2014 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Resistant cell line consisted of a 70% side population fraction enriched with Oct4-positive cancer stem cells.
|
20596658 |
2010 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
We further demonstrated that inactivation of p38 is a potential mechanism contributing to acquisition and maintenance of cancer stem cell properties in non-small cell lung cancer (NSCLC) cells. p38, in particular the p38γ and p38δ isoforms, suppresses the cancer stem cell properties and tumor initiating ability of NSCLC cells by promoting the ubiquitylation and degradation of stemness proteins such as SOX2, Oct4, Nanog, Klf4 and c-Myc, through MK2-mediated phosphorylation of Hsp27 that is an essential component of the proteasomal degradation machinery.
|
28460458 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Treatment of tumor-bearing mice with genotoxic chemotherapy not only prolonged survival and reduced tumor size but also selectively eliminated the OCT4-positive cancer stem cells.
|
29141221 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy.
|
31786016 |
2019 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Here, we initially showed that HBV stimulates the production of cancer stem cells (CSCs)-related markers (CD133, CD117 and CD90) and CSCs-related genes (Klf4, Sox2, Nanog, c-Myc and Oct4) and facilitates the self-renewal of CSCs in human hepatoma cells.
|
28455240 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Recent studies found that the stem cell-related genes Sox2, Oct4 and Klf4 are among the target genes regulated by microRNA-145 (miR-145), suggesting that miR-145 possibly plays a role in the maintenance of cancer stem cells.
|
22378186 |
2012 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
A strategy to target "cancer stem cells" is to suppress the Oct-4 gene in order to cause the cells to differentiate.
|
17261754 |
2006 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The gene and protein expression levels of pluripotent stem cell markers (Tra-1-60, Oct4, Nanog) and cancer stem cell markers (CD133, CD44) were up-regulated in transduced Rbc51 cells compared to control cells.
|
27856246 |
2017 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Oct4 promotes cancer cell proliferation and migration and leads to poor prognosis associated with the survivin/STAT3 pathway in hepatocellular carcinoma.
|
29901157 |
2018 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The implications are either in vivo existence of Oct4 positive putative cancer stem cells in ESCC or acquisition of cancer stem cell properties by tumor cells as a response to treatment given, resulting ultimately an uncontrolled cell proliferation and treatment failure.
|
24870750 |
2014 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The BORIS-positive cells isolated using BORIS-molecular beacon, expressed higher telomerase hTERT, stem cell (NANOG, OCT4, SOX2) and cancer stem cell marker genes (CD44 and ALDH1) compared to the BORIS-negative tumor cells.
|
25279549 |
2014 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Octamer-binding transcription factor 4 (OCT4) has been implicated in cancer metastasis.
|
23076549 |
2013 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Taken together, these evidences suggest that miR-145 serves as a tumor suppressor which downregulates LCICs' cancer stem cell properties and EMT process by targeting Oct4, leading to the inhibition of tumor growth and metastasis.
|
24903381 |
2014 |
|
POU5F1P3
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
In addition, immunohistochemical studies on mouse tumors injected with cisplatin or paclitaxel treated residual cells displayed higher staining for the proliferative antigen Ki67, oncogeneic CA125, epithelial E-cadherin as well as cancer stem cell markers such as Oct4 and CD117, compared to mice injected with control untreated cells.
|
23537295 |
2013 |